title: Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease.
abstract: During the recent years, projects are in progress for designing broad-range non-capsular-based meningococcal vaccines, covering also serogroup B isolates. We have examined three genes encoding antigens (NadA, GNA1030 and GNA2091) included in a novel vaccine, i.e. the 5 Component Vaccine against Meningococcus B (5CVMB), in terms of gene prevalence and sequence variations. These data were combined with the results from a similar study, examining the two additional antigens included in the 5CVMB (fHbp and GNA2132). nadA and fHbp v. 1 were present in 38% (n=36), respectively 71% (n=67) of the isolates, whereas gna2132, gna1030 and gna2091 were present in all the Neisseria meningitidis isolates tested (n=95). The level of amino acid conservation was relatively high in GNA1030 (93%), GNA2091 (92%), and within the main variants of NadA and fHbp. GNA2132 (54% of the amino acids conserved) appeared to be the most diversified antigen. Consequently, the theoretical coverage of the 5CVMB antigens and the feasibility to use these in a broad-range meningococcal vaccine is appealing.
authors.affiliation: National Reference Laboratory for Pathogenic Neisseria, Department of Clinical Microbiology, Orebro University Hospital, SE-701 85 Orebro, Sweden. susanne.jacobsson@orebroll.se
authors.forename: Susanne
authors.initials: S
authors.lastname: Jacobsson
authors.forename: Sara Thulin
authors.initials: ST
authors.lastname: Hedberg
authors.forename: Paula
authors.initials: P
authors.lastname: Mölling
authors.forename: Magnus
authors.initials: M
authors.lastname: Unemo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Comanducci
authors.forename: Rino
authors.initials: R
authors.lastname: Rappuoli
authors.forename: Per
authors.initials: P
authors.lastname: Olcén
mesh_terms: D000595:Amino Acid Sequence; D000942:Antigens, Bacterial / Q000235:genetics*; D001483:Base Sequence; D017124:Conserved Sequence; D017931:DNA Primers / Q000235:genetics; D004269:DNA, Bacterial / Q000235:genetics; D005798:Genes, Bacterial; D014644:Genetic Variation; D006801:Humans; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D008589:Meningococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000235:genetics* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D010802:Phylogeny
chemical_list: D000942:Antigens, Bacterial; D017931:DNA Primers; D004269:DNA, Bacterial; D022401:Meningococcal Vaccines